The discovery of receptor tyrosine kinases: targets for cancer therapy

By A. Gschwind, O. Fischer, A. Ullrich. Nature Reviews. Cancer, 2004

1,260 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/53319ba0d9c4232e9690048c9e88012a409801e7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. A. Adamis
2. N. Hynes
3. N. Ferrara
4. C. Blobel
5. Carlos L. Arteaga
6. P. Johnston
7. D. Longley
8. C. Abate-Shen

In Oncology

1. N. Hynes
2. A. Adamis
3. Carlos L. Arteaga
4. C. Blobel
5. N. Ferrara
6. P. Johnston
7. D. Longley
8. C. Abate-Shen

In Radiology, Nuclear Medicine and Imaging

1. N. Hynes
2. Carlos L. Arteaga
3. C. Blobel
4. N. Ferrara
5. P. Johnston
6. D. Longley
7. M. Sliwkowski
8. A. Adamis

Citations in the corpus

• Treatment of HER2-positive breast cancer: current status and future perspectives (2012, background): “177" language="eng" relation="no"> Introduction HER2 is a transmembrane receptor with tyrosine kinase activity but without a known ligand that was initially identified in a rat glioblastoma model”
• Ten years of anti-vascular endothelial growth factor therapy (2016, methodology): “In addition to using monoclonal antibodies 11 , alternative approaches of inhibiting the VEGFA– VEGFR pathway for the treatment of cancer have been explored 103 .”
• Urothelial tumorigenesis: a tale of divergent pathways (2005, background): “Activation of the RTK–Ras pathway The receptor tyrosine kinase (RTK)–Ras pathway plays a central part in the proliferation and renewal of epithelial cells by transducing mitogenic signals from the cell surface to the nucleus (reviewed in Ref”
• ERBB receptors and cancer: the complexity of targeted inhibitors (2005, background): “ERBB receptors and cancer The ERBB receptors are implicated in the development of many types of cancer, and EGFR was the first tyrosine-kinase receptor to be linked directly to human tumours (for a timeline on EGFR and cancer see Ref”
• Molecular genetics of prostate cancer: new prospects for old challenges. (2010, background): “The deregulated expression of oncogenic tyrosine kinases has been studied extensively in many cancers, since these can represent targets for therapeutic intervention (Gschwind et al. 2004).”
• Revisiting the hallmarks of cancer. (2017, neutral): “[25] Gschwind A, Fischer OM and Ullrich A.”
• Molecular mechanisms of drug resistance (2005, background): “Another EGFR inhibitor, cetuximab (C225), is in phase III trials in combination with chemotherapy in advanced colorectal cancer [213,215].”
• ADAMs: key components in EGFR signalling and development (2005, background): “pl?P00533">EGFR ) — a tyrosine kinase receptor with important roles in development and in diseases such as cance”